Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer
Yan Wang, Dongmei Chen, Zhenning Wang, Xiaoye Jin, Jiao Zhang, Ye Lv · 2026
Read Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer by Yan Wang, Dongmei Chen, Zhenning Wang, Xiaoye Jin, Jiao Zhang, Ye Lv (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13207859.txt.
Description
For advanced breast cancer that feeds on hormones but lacks the HER2 marker, pairing hormone therapy with CDK4/6 blockers has become a leading option. Yan Wang and co-authors check how well that pairing works in their hospital's records. They compare 83 patients on the combined treatment with 62 on hormone therapy alone, all with hormone-positive, HER2-negative advanced disease.
The combined group did better on every measure. Tumors shrank in 45.8 percent against 22.6 percent, and disease was controlled in 84.3 percent against 67.7 percent. Median time before the cancer grew again was fifteen months against nine, and median survival was 20.5 months against 9.5. Higher estrogen receptor levels protected patients, while spread to the liver raised risk. Side effects stayed manageable, and the authors judge the pairing effective and acceptably safe.
Catalog record
| CREATOR | Yan Wang, Dongmei Chen, Zhenning Wang, Xiaoye Jin, Jiao Zhang, Ye Lv |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |